Aino Health AB (publ): Aino Health's planned listing on Nasdaq First North
27.11.2016 18:01 | NASDAQ OMX
November 27, 2016
NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, TO NEWS DISTRIBUTORS IN THE UNITED STATES, OR FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD NOT BE ALLOWED BY APPLICABLE LAW.
Aino Health's planned listing on Nasdaq First North
The Board of Directors in Aino Health AB (publ) ("Aino Health" or the "Company") has decided to apply for listing of the Company's shares on Nasdaq First North, and in connection with the listing the Board of Directors has decided on a share issue of up to 2,070,000 newly issued shares directed to the general public and institutional investors (the "Offer"), whereby the Company will receive a maximum of SEK 48.8 M after transaction costs. A prospectus relating to the Offer will be published on November 27, 2016. Preliminary first day of trading is on December 16, 2016.
The total value of the Offer, if fully subscribed, amounts to SEK 53.8 M distributed on 1,800,000 newly issued shares (the "Share Issue") and an over-allotment of up to 270,000 existing shares at a share price of 26.00 SEK (the "Over-allotment"). The Over-allotment can be exercised in the event of a major interest in the Offer. The Over-allotment is implemented as a part of stabilization, after which the Company may issue an additional 270,000 shares through the Over-allotment option directed to Erik Penser Bank.
A number of investors have agreed to share subscription agreements of SEK 31.9 M, corresponding to approximately 68 percent of the Offer excluding the Over-allotment.
Aino Health's business concept is to increase health awareness in various organizations and to reduce personnel sickness absence by promoting an IT-based process solution to both private and public companies and organizations. The Company provides services and tools for the entire value chain of health- and safety management as well as related services, processes and methods.
The social need to improve the population health eg by reducing sickness absence levels places new demands on employers and creates the need for new solutions. Being innovative and offering modern solutions, Aino Health enables a revolutionary and effective health management for companies and organizations. This means that Aino Health's potential client base is very large.
The Offer constitutes of up to 1,800,000 newly issued shares and an Over-allotment of up to 270,000 existing shares in the event of major interest in the Offer
The share price is 26.00 SEK per share, corresponding to a pre-money equity valuation of approximately SEK 94.2 M (EUR 9.6 M)
Erik Penser Bank will, during a period of 30 days from the first day of trading on Nasdaq First North, engage in transactions that stabilize, maintain or otherwise affect the price of the shares.
The Company has, within the frame of the stabilization, agreed on an Over-allotment option to Erik Penser Bank to issue additional 270,000 shares
The number of shares in the Company will increase with up to 2,070,000 shares, corresponding to 36 percent of the total number of shares in the Company after the completion of the Offer
The Offer amounts to SEK 46.8 M and SEK 53.8 M if the Over-allotment is fully exercised. The Company will receive up to SEK 48.8 M after transaction costs of SEK 5.0 M
Aino Health has applied for listing of the Company's shares on Nasdaq First North and preliminary first day of trading on December 16, 2016
A prospectus with full terms has been published today on November 27, 2016 and is available on Aino Health's website, www.ainohealth.com
Indicative time schedule
Subscription period: November 28 - December 8, 2016
Publication of the result: December 9, 2016
Preliminary first day of trading: December 16, 2016
Background and reasons
Aino Health Management Oy was founded in Finland in 1994 and has been operating its current business model since 2010. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.
The general corporate health level is most often expressed in terms of sickness absences and measured in terms of sick pay costs and salaries to substitutes. Furthermore, there are additional costs that are hard to measure such as reduced quality of delivered products and services as a consequence of a changing and unstable workforce, as a result of the general state at the work place, in full and in working groups.
A complete service provided by Aino Health includes:
Integration of the customer's personnel records and Aino Health's central IT-based database, Health Manager
HealthManager collects and analyses personnel data including suggestions for actions when the sickness absence reach a certain level as well as monitoring of supervisors and managers' actions and signal of possible passivity regarding personnel sickness absences
Sickness absence reporting and personal follow-up by qualified medical personnel through the Aino Health Call center/Health Desk
SafetyManager, to be launched in 2017, will serve as the customer's integrated solution for health and safety management in different organizations including registration, monitoring and reporting to top level management of events and processes related to the company safety and working environment
Aino Health's systems can be described as tools and services to be able to establish and maintain low sickness absence levels and reduce costs through ensuring that the employees get the attention needed when they are absent. Underlying reasons and patterns of the sickness absence are being monitored in consultation with employees and unions, and any passivity from managers can quickly be detected. Sickness absence can be a complex problem and can be explained by both obvious and hidden causes.
The subsidiary, Aino Health Management Oy, has established a reputable client base consisting of both private and public organizations in Finland. The customer base consists of approximately 150 customers, and around 30 customers with approximately 33 000 employees combined are using the HealthManager service. In 2015, 20 percent of Aino Health's customers accounted for about 85 percent of the turnover.
Aino Health is facing an expansion with the aim of further establishment in Europe. The first step will be a market launch in Sweden and Germany where discussions and negotiations with a number of potential customers have been initiated.
The current corporate structure consists of the parent company Aino Health AB (publ), the Swedish subsidiary Aino Health Sweden AB and the fully owned Finnish subsidiary Aino Health Management Oy with its subsidiary Aino Active Oy. The corporate group will be expanded and a new subsidiary will be established in each new country Aino Health enters.
Aino Health's objective is to achieve a strong growth, partly by growing organically in already established markets and partly through entering new geographical markets. The objective is that establishments on new markets should be self-financing without the need for additional capital after two years.
The Board of Directors in Aino Health has, to provide the Company with sufficient working capital and strengthen the financial position, on November 21, 2016 decided on the Offer based on EGM's approval on September 19, 2016. The Offer amounts to a total of SEK 53.8 M if fully subscribed and including the Over-allotment option, after which the Company will receive up to SEK 48.8 M after transaction costs of SEK 5.0 M. The proceeds will be utilized for working capital with the exception of 1-2 million relating to adjustments of software.
The offer and the subsequent listing on Nasdaq First North will create liquidity in the Aino Health share. The listing of Aino Health will grant the company access to the stock market, which facilitates future fund raising. The listing also enables Aino Health to, over time, get new shareholders that could strengthen the company development. The listing is also expected to have positive effects on the company's relationships with business partners, employees and potential clients. The Board of Directors of Aino Health assess that the company is well suited for a broadening of ownership and listing of shares.
Aktiespararna Aino Health will be presented at Aktiespararnas aktiedagar in Stockholm Monday, November 28. Additional information on www.aktiespararna.se/evenemang
Stockholm Presentation, Monday December 5 at 17:30, Erik Penser Bank, Apelbergsgatan 27. Sign up on email@example.com
Stockholm Lunch presentation Tuesday December 6 at 12:00, Erik Penser Bank, Apelbergsgatan 27. Sign up on firstname.lastname@example.org
Prospectus and application forms
The prospectus with the terms and instructions and application forms are available on the Company's website (www.ainohealth.com) and at Erik Penser Bank's website (www.penser.se). The prospectus can be ordered, free of charge, by e-mail; email@example.com. An application can also be made via Skandiabanken, www.skandia.se.
Erik Penser AB is the financial advisor and Advokatfirman Lindahl KB is the legal adviser in the Offer. Erik Penser AB is Certified Adviser.
This information is information that Aino Health AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at November 27 CET on 18:00 2016.
For more information, please contact:
Jyrki Eklund, CEO
Phone: +358 40 042 4221
About Aino Health
Aino Health operates within Corporate Health Management. The company has developed a complete system of IT-based services with a focus to improve corporate health and reduce sickness absence levels in private and public organizations.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aino Health AB (publ) via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Promethean Opens New Global Headquarters in Seattle18.8.2017 18:38 | Pressmeddelande
Seattle, Wash., Aug. 18, 2017 (GLOBE NEWSWIRE) -- PrometheanTM, a global education technology company, announced today the opening of its new global headquarters in Seattle, Wash. Promethean's office in Atlanta, Ga. will continue to serve as the hub for the Americas markets, and the Blackburn, U.K. office will continue to carry on as the hub for the EMEA markets and parts of Asia. Promethean is one of the leading brands in the international education technology market with more than 20 years of experience in the K-12 classroom. Its solutions are in more than 50,000 schools and institutions in 154 countries. "As traditional pedagogy continues to move towards immersive learning, it's important for Promethean to lead innovation in education with the latest technology," said Vin Riera, CEO of Promethean. "Seattle is a global technology hub, and establishing Promethean's global headquarters there increases opportunities for new business models, concepts
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00 | Pressmeddelande
Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressmeddelande
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressmeddelande
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressmeddelande
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40 | Pressmeddelande
Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum